Lumida
/SMMT
⌘K
Summit Therapeutics Inc

Summit Therapeutics Inc

SMMT
$17.55USD+3.24%+0.55 today

MARKET CAP

14.0B

P/E (TTM)

FWD P/E

DAY RANGE

$17 – $18

52W RANGE

$12
$29

AI Summary

Stalk
StalkMedium

SMMT has triggered a clear momentum breakout and exhibits bullish medium-term structure supported by active continuation patterns. However, price is extended above rising EMAs with extreme overbought readings, warranting patience. A deferred buy on pullbacks into the rising 9/20 EMA zone aligns with speculative strategy discipline and manages risk against the longer-term downtrend.

  • Ibanesimab delivered statistically significant PFS in four Phase III trials.
  • $690.7M cash balance and zero debt fund PDUFA readiness.
  • Approval uncertain without statistically significant overall survival benefit.
Full analysis →
Sales, Adj.
Gross Profit, Adj.
EBITDA, Adj.
EBIT
Net Income